Please login to the form below

Not currently logged in
Email:
Password:

Deloitte

This page shows the latest Deloitte news and features for those working in and with pharma, biotech and healthcare.

NHS bracing for 'no deal’ Brexit impact, including medicines

NHS bracing for 'no deal’ Brexit impact, including medicines

According to a Deloitte survey, 75% of British companies are now pessimistic about Brexit after weak investment and waning revenues in the most recent financial quarter.

Latest news

  • Health insurers will test blockchain for data handling Health insurers will test blockchain for data handling

    A Deloitte report on the application of blockchain to healthcare published in 2016 predicted that the technology could “provide a new model for health information exchanges (HIE) by making electronic medical

  • Pharma is ‘getting lower returns on R&D’ Pharma is ‘getting lower returns on R&D’

    Pharma is ‘ getting lower returns on R&D’. And Deloitte says the number of drugs in late-stage trials tumbled by 16%. ... almost $2bn compared to $1.2bn in 2010 when the annual survey - by Deloitte’s Centre for Health Solutions - was first conducted

  • Real-world evidence Real-world evidence

    life science partner and RWE specialist at analysts Deloitte. “

  • Brexit: Medical research and the EU referendum Brexit: Medical research and the EU referendum

    In the interests of balance. In February, Karen Taylor, research director for Deloitte's UK Centre for Health Solutions, authored a corporate blog on the potential impact of Brexit for the

  • Study shows R&D returns too low in pharma to be sustainable Study shows R&D returns too low in pharma to be sustainable

    The numbers simply do not add up for life sciences R&D to generate an appropriate return," notes Deloitte. ... While the outlook shows uncertain times for the industry, the solutions appear to be relatively straightforward," commented Neil Lesser, life

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • The Big Book of Dashboards The Big Book of Dashboards

    Steve Wexler has worked with ADP, Gallup, Deloitte, Convergys, Consumer Reports, The Economist, ConEd, D&B, Marist, Tradeweb, Tiffany, McKinsey &Company, and many other organisations to help them understand and visualise

  • The rise of real-world evidence The rise of real-world evidence

    More than half the leading life science companies polled by Deloitte in 2017 were developing or significantly improving their real-world data (RWD) capabilities.

  • A quest for innovative solutions A quest for innovative solutions

    The report from analysts Deloitte in December last year, A New Future for R&D?, highlighted diminishing revenue returns from traditional drug development models but stated: ‘We see opportunities for biopharma

  • Digitally yours: How to build effective relationships in virtual space Digitally yours: How to build effective relationships in virtual space

    It is not all about saving though. A 2015 Deloitte forecast estimates considerable growth opportunities in the global mobile and digital health market, with a forecasted rise from $2.4 billion

  • Deal Watch December 2015 Deal Watch December 2015

    December saw the release of reports by two of the top accountancy and consulting groups, PWC and Deloitte. ... Deloitte and GlobalData's report Measuring the return from pharmaceutical innovation 2015 - transforming R&D returns in uncertain times

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics